FDA Manufacturing Supplement Proposal To Be Discussed By Advisory Cmte.
This article was originally published in The Tan Sheet
Executive Summary
FDA's Pharmaceutical Sciences Advisory Committee will discuss the agency's proposal to reduce post-approval manufacturing change reporting requirements for "qualified " products during a Nov. 15-17 meeting.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning